Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Correction: Landscape of mast cell populations across organs in mice and humans. | J Exp Med | 2024 | 38265438 | PubTator, text mining | PubMed |
| ST2-Mediated Neutrophilic Airway Inflammation: A Therapeutic Target for Patients With Uncontrolled Asthma. | Allergy Asthma Immunol Res | 2024 | 38262389 | PubTator, text mining | PubMed |
| Next-Generation Therapeutic Approaches for Uncontrolled Asthma: Insights Into the Heterogeneity of Non-Type 2 Inflammation. | Allergy Asthma Immunol Res | 2024 | 38262386 | PubTator, text mining | PubMed |
| Successful Introduction of Benralizumab for Eosinophilic Ascites. | Biomedicines | 2024 | 38255222 | PubTator, text mining | PubMed |
| Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities. | Biomolecules | 2024 | 38254726 | PubTator, text mining | PubMed |
| Biological Anti-IL-5/IL-5R Therapeutics for Chronic Obstructive Pulmonary Disease (COPD) with Specific Treatable Traits: A Real-World Retrospective Analysis. | Int J Chron Obstruct Pulmon Dis | 2024 | 38249820 | PubTator, text mining | PubMed |
| Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis. | J Allergy Clin Immunol Pract | 2024 | 38211889 | PubTator, text mining | PubMed |
| Epithelial IL5RA promotes epithelial-mesenchymal transition in pulmonary fibrosis via Jak2/STAT3 cascade. | Pulm Pharmacol Ther | 2024 | 38191068 | PubTator, text mining | PubMed |
| Predictors of persistent poor control and validation of ASSESS score: Longitudinal 5-year follow-up of severe asthma cohort. | J Allergy Clin Immunol Glob | 2024 | 38173699 | PubTator, text mining | PubMed |
| Eosinophil to lymphocyte ratio may predict OCS reduction and change in quality of life (AQLQ) resulting from asthma biological treatment. | Immunopharmacol Immunotoxicol | 2024 | 38151952 | PubTator, text mining | PubMed |
| Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum. | EBioMedicine | 2024 | 38128411 | PubTator, text mining | PubMed |
| Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients. | Arch Bronconeumol | 2024 | 38042707 | PubTator, text mining | PubMed |
| Chronic rhinosinusitis with nasal polyps: eosinophils versus B lymphocytes in disease pathogenesis. | Curr Opin Allergy Clin Immunol | 2024 | 38018818 | PubTator, text mining | PubMed |
| Tailored Biologics Selection in Severe Asthma. | Tuberc Respir Dis (Seoul) | 2024 | 38018037 | PubTator, text mining | PubMed |
| Structure-based improvement of the binding affinity and recognition specificity of peptide competitors to target pediatric IL-5R/IL-5 interaction by gluing halogen bonds at their complex interface. | J Mol Recognit | 2024 | 37990248 | PubTator, text mining | PubMed |
| Peripheral Blood IL5RA Gene Expression as a Diagnostic Biomarker for Eosinophilic Esophagitis. | Clin Gastroenterol Hepatol | 2024 | 37944574 | PubTator, text mining | PubMed |
| Molecular design and systematic optimization of a halogen-bonding system between the asthma interleukin-5 receptor and its cyclic peptide ligand. | Chem Biol Drug Des | 2024 | 37926515 | PubTator, text mining | PubMed |
| The effect of biologics in lung function and quality of life of patients with united airways disease: A systematic review. | J Allergy Clin Immunol Glob | 2024 | 37915724 | PubTator, text mining | PubMed |
| Nasal polyp antibody-secreting cells display proliferation signature in aspirin-exacerbated respiratory disease. | J Allergy Clin Immunol | 2024 | 37898408 | PubTator, text mining | PubMed |
| Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives. | Auris Nasus Larynx | 2024 | 37743131 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers?page=12